Heart failure study unlocks metabolic secrets of common drug
NCT ID NCT05885607
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how SGLT2 inhibitors, a type of diabetes drug also used for heart failure, affect the body's metabolism. About 40 adults with mild to moderate heart failure will have blood tests, walking tests, and calf MRIs before and after starting the medication. The goal is to understand early changes in energy use and muscle function, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?